| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.06 | 0.00 (0.00%) | 3.35 - 5.11 | 9.5 thousand (Below Avg) |
Market data as of 4:00PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 4.06 |
| Day's Range | -- - -- |
| Market Cap | 228.5M |
| Avg Volume (10 Day) | 203.5K |
| Price/Earnings (Trailing 12 Mo.) | 29.0x |
| Earnings Per Share (Trailing 12 Mo.) | 0.14 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
RTI Biologics Announces 2013 First Quarter Results
Business Wire - Thursday 04/25/2013 8:09 AM ET
| RTIX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 1.38% | |
| Net Income Growth (1yr) | 388.80% | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 3.45% | |
| Price/Sales | 1.31 |
| Company | Last | Change |
|---|---|---|
| Exactech Inc | 17.90 | 0.00% |
| Palomar Medical Technologies Inc | 13.44 | 0.00% |
| ZELTIQ Aesthetics Inc | 5.08 | 0.00% |
| CryoLife Inc | 6.31 | 0.00% |
| Navidea Biopharmaceuticals Inc | 2.40 | 0.00% |
Data is delayed by at least 15 min.